The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer

International Journal of Biological Markers

Volumn 21, Issue 4, 2006, Pages 229-234

  Grimaldi, F ^a   Valotto, C ^b   Barbina, G ^a   Visentini, D ^a   Trianni, A ^a   Cerruto, M A ^c   Zattoni, Filiberto ^c,d  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Rehabilitation Unit   (Italy)

Author keywords

Chromogranin A; Localized prostate cancer; Neuroendocrine differentiation; Neuron specific enolase; Prognostic factors

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE SYSTEM; PHENOTYPE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION;

EID: 33846480684     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5160     Document Type: Article

References (26)

1. DeAngelis R, Capocaccia R, Verdecchia A. Estimating relative survival of Italian cancer patients from sparse cancer registries data. Tumori 1997; 83: 33-8.
2. Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003; 4: 215-21.
3. Cohen RJ, Glezerson G, Haffejee Z, Afrika D. Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol 1990; 66: 405-10.
4. Di Sant'Agnese PA, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78: 357-61.
5. Ferrero-Poüs M, Hersant AM, Pecking A, Brésard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. Br J Urol 2001; 88: 790-6.
6. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-17.
7. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-7.
8. Hossein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993; 149: 1209-13.
9. Bonkhoff H. Neuroendocrine calls in benign and malignant prostatic tissue. Morphogenesis, proliferation, and androgen receptor status. Prostate 1998; 23 (Suppl 8): 18-22.
10. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OKR, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997; 31: 110-7.
11. Prostate. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002; 309-16.
12. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-58.
13. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992; 23: 273-8.
14. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumours. Prostate Suppl 1998; 8: 43-51.
15. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27:683-7.
16. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155: 1340-3.
17. Sciarra A, Monti S, Gentile V, Cardi A, Voria G, Di Silverio F. Variation in chromogranin A levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55: 168-79.
18. Bollito E, Berruti A, Bellina M, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001; 12 (Suppl 2): S159-64.
19. Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70 (1 Suppl): S254-68.
20. Abrahamsson PA, Cockett AT, Di Sant'Agnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 1998; 8: 37-42.
21. Italian Network for Quality Assessment of Tumor Biomarkers (INQAT) Group. An Italian program of external quality control for chromogranin A (CgA): State of the art of CgA measurement. Int J Biol Markers 20: 264-8.
22. Leon A, Torta M, Dittadi R, et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): Results of a prospective multicenter observational study. Int J Biol Markers 2005; 20: 156-68.
23. Sciarra A, Voria G, Monti S, et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 2004; 58: 421-8.
24. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 1555: 1340-3.
25. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001; 46: 126-33.
26. Slodkowska J, Zych J, Szturmowicz M, et al. Neuroendocrine phenotype of small cell lung carcinoma: immunohistological evaluation and biochemical study. Int J Biol Markers 2005; 20: 217-26.